|
1
|
Westphal M and Lamszus K: The neurobiology
of gliomas: From cell biology to the development of therapeutic
approaches. Nat Rev Neurosci. 12:495–508. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Furnari FB, Fenton T, Bachoo RM, Mukasa A,
Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al:
Malignant astrocytic glioma: Genetics, biology, and paths to
treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pollack IF: Neuro-oncology: Therapeutic
benefits of reirradiation for recurrent brain tumors. Nat Rev
Neurol. 6:533–535. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pang JC, Kwok WK, Chen Z and Ng HK:
Oncogenic role of microRNAs in brain tumors. Acta Neuropathol.
117:599–611. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Silber J, James CD and Hodgson JG:
microRNAs in gliomas: Small regulators of a big problem.
Neuromolecular Med. 11:208–222. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: microRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Manikandan J, Aarthi JJ, Kumar SD and
Pushparaj PN: Oncomirs: The potential role of non-coding microRNAs
in understanding cancer. Bioinformation. 2:330–334. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Y, Dutta A and Abounader R: The role
of microRNAs in glioma initiation and progression. Front Biosci.
17:700–712. 2012. View
Article : Google Scholar
|
|
11
|
Besse A, Sana J, Fadrus P and Slaby O:
MicroRNAs involved in chemo- and radioresistance of high-grade
gliomas. Tumour Biol. 34:1969–1978. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu QQ, Ma C, Wang Q, Song Y and Lv T: The
role of TWIST1 in epithelial-mesenchymal transition and cancers.
Tumour Biol. 37:185–197. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kang Y and Massagué J:
Epithelial-mesenchymal transitions: Twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tam WL and Weinberg RA: The epigenetics of
epithelial-mesenchymal plasticity in cancer. Nat Med. 19:1438–1449.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Taube JH, Herschkowitz JI, Komurov K, Zhou
AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, et
al: Core epithelial-to-mesenchymal transition interactome
gene-expression signature is associated with claudin-low and
metaplastic breast cancer subtypes. Proc Natl Acad Sci USA.
107:15449–15454. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang MH and Wu KJ: TWIST activation by
hypoxia inducible factor-1 (HIF-1): Implications in metastasis and
development. Cell Cycle. 7:2090–2096. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Elias MC, Tozer KR, Silber JR, Mikheeva S,
Deng M, Morrison RS, Manning TC, Silbergeld DL, Glackin CA, Reh TA,
et al: TWIST is expressed in human gliomas and promotes invasion.
Neoplasia. 7:824–837. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nordfors K, Haapasalo J, Mäkelä K,
Granberg KJ, Nykter M, Korja M, Paavonen T, Haapasalo H and Soini
Y: Twist predicts poor outcome of patients with astrocytic glioma.
J Clin Pathol. 68:905–912. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mikheeva SA, Mikheev AM, Petit A, Beyer R,
Oxford RG, Khorasani L, Maxwell JP, Glackin CA, Wakimoto H,
González-Herrero I, et al: TWIST1 promotes invasion through
mesenchymal change in human glioblastoma. Mol Cancer. 9:1942010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun JJ, Chen GY and Xie ZT:
MicroRNA-361-5p inhibits cancer cell growth by targeting CXCR6 in
hepatocellular carcinoma. Cell Physiol Biochem. 38:777–785. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu D, Tao T, Xu B, Chen S, Liu C, Zhang
L, Lu K, Huang Y, Jiang L, Zhang X, et al: MiR-361-5p acts as a
tumor suppressor in prostate cancer by targeting signal transducer
and activator of transcription-6 (STAT6). Biochem Biophys Res
Commun. 445:151–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma F, Song H, Guo B, Zhang Y, Zheng Y, Lin
C, Wu Y, Guan G, Sha R, Zhou Q, et al: MiR-361-5p inhibits
colorectal and gastric cancer growth and metastasis by targeting
staphylococcal nuclease domain containing-1. Oncotarget.
6:17404–17416. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY,
Yang WH, Huang CH, Kao SY, Tzeng CH, Tai SK, et al: Bmi1 is
essential in Twist1-induced epithelial-mesenchymal transition. Nat
Cell Biol. 12:982–992. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kwak PB, Iwasaki S and Tomari Y: The
microRNA pathway and cancer. Cancer Sci. 101:2309–2315. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Karsy M, Arslan E and Moy F: Current
progress on understanding microRNAs in glioblastoma multiforme.
Genes Cancer. 3:3–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tivnan A and McDonald KL: Current progress
for the use of miRNAs in glioblastoma treatment. Mol Neurobiol.
48:757–768. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kanitz A, Imig J, Dziunycz PJ, Primorac A,
Galgano A, Hofbauer GF, Gerber AP and Detmar M: The expression
levels of microRNA-361-5p and its target VEGFA are inversely
correlated in human cutaneous squamous cell carcinoma. PLoS One.
7:e495682012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu X, Xi X, Yan Q, Zhang Z, Cai B, Lu W
and Wan X: MicroRNA-361-5p facilitates cervical cancer progression
through mediation of epithelial-to-mesenchymal transition. Med
Oncol. 30:7512013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW,
Che N, Wang XH, Du J, Liu YX and Sun BC: Expression and functional
significance of Twist1 in hepatocellular carcinoma: Its role in
vasculogenic mimicry. Hepatology. 51:545–556. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Haga CL and Phinney DG: MicroRNAs in the
imprinted DLK1-DIO3 region repress the epithelial-to-mesenchymal
transition by targeting the TWIST1 protein signaling network. J
Biol Chem. 287:42695–42707. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin Y, Liu AY, Fan C, Zheng H, Li Y, Zhang
C, Wu S, Yu D, Huang Z, Liu F, et al: MicroRNA-33b inhibits breast
cancer metastasis by targeting HMGA2, SALL4 and Twist1. Sci Rep.
5:99952015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sun X, Cui M, Zhang A, Tong L, Wang K, Li
K, Wang X, Sun Z and Zhang H: MiR-548c impairs migration and
invasion of endometrial and ovarian cancer cells via downregulation
of Twist. J Exp Clin Cancer Res. 35:102016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu H, Wang H, Liu X and Yu T: miR-1271
inhibits migration, invasion and epithelial-mesenchymal transition
by targeting ZEB1 and TWIST1 in pancreatic cancer cells. Biochem
Biophys Res Commun. 472:346–352. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao X, Wang Y, Deng R, Zhang H, Dou J,
Yuan H, Hou G, Du Y, Chen Q and Yu J: miR186 suppresses prostate
cancer progression by targeting Twist1. Oncotarget. 7:33136–33151.
2016.PubMed/NCBI
|
